IMPLEMENTING A VIRTUAL NEPHROLOGY PANEL FOR TOLVAPTAN USE IN PATIENTS WITH ADPKD

被引：0
|
作者：
Lin Duong [1 ]
Taneja, Nidhika [1 ]
Belani, Sharina [1 ]
Irannejad, Pardis [1 ]
Jain, Anagha [1 ]
Lieberman, Jonathan [1 ]
Tuan Nguyen [1 ]
Ramaswamy, Deepa [1 ]
机构：
[1] Kaiser Permanente Northern Calif, Oakland, CA USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2021年 / 77卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
75
引用
收藏
页码：590 / 590
页数：1
相关论文
共 50 条
  • [41] Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life
    Todorova, Polina
    Arjune, Sita
    Hendrix, Claudia
    Oehm, Simon
    Schmidt, Johannes
    Krauss, Denise
    Burkert, Katharina
    Burst, Volker Rolf
    Benzing, Thomas
    Boehm, Volker
    Grundmann, Franziska
    Mueller, Roman-Ulrich
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (08): : 1616 - 1626
  • [42] ADAPTING THE ADPKD OUTCOMES MODEL TO PREDICT COST CONSEQUENCE IN ITALIAN PATIENTS WITH AUTOS OMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) TREATED WITH JINARC (TOLVAPTAN)
    Mennini, F. S.
    Marcellusi, A.
    Russo, S.
    Iorio, A.
    Lanati, E. P.
    Robinson, P.
    VALUE IN HEALTH, 2015, 18 (07) : A755 - A755
  • [43] Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
    Kramers, Bart J.
    van Gastel, Maatje D. A.
    Boertien, Wendy E.
    Meijer, Esther
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (03) : 354 - 362
  • [44] Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients
    Bargagli, Matteo
    Vetsch, Andri
    Anderegg, Manuel A.
    Dhayat, Nasser A.
    Huynh-Do, Uyen
    Faller, Nicolas
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (07) : 1645 - 1654
  • [45] Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD
    Akihisa, Taro
    Kataoka, Hiroshi
    Makabe, Shiho
    Manabe, Shun
    Yoshida, Rie
    Ushio, Yusuke
    Sato, Masayo
    Yajima, Aiji
    Hanafusa, Norio
    Tsuchiya, Ken
    Nitta, Kosaku
    Hoshino, Junichi
    Mochizuki, Toshio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (06) : 1008 - 1015
  • [46] DETERMINANTS OF URINE VOLUME IN ADPKD-PATIENTS USING THE VASOPRESSIN V2 RECEPTOR ANTAGONIST TOLVAPTAN
    Kramers, Bart
    Heida, Judith
    Boertien, Wendy
    van Gastel, Maatje
    Meijer, Esther
    Gansevoort, Ron
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [47] COST-EFFECTIVENESS OF TOLVAPTAN IN CANADIAN PATIENTS WITH AUTOSOMAL POLYCYSTIC KIDNEY DISEASE: AN ADAPTATION OF THE ADPKD OUTCOMES MODEL
    Xu, M. K.
    Sauriol, S.
    O'Reilly, K.
    VALUE IN HEALTH, 2018, 21 : S477 - S477
  • [48] The Role of Baseline Total Kidney Volume Growth Rate in Predicting Tolvaptan Efficacy for ADPKD Patients: A Feasibility Study
    Dev, Hreedi
    Hu, Zhongxiu
    Blumenfeld, Jon D.
    Sharbatdaran, Arman
    Kim, Yelynn
    Zhu, Chenglin
    Shimonov, Daniil
    Chevalier, James M.
    Donahue, Stephanie
    Wu, Alan
    Roychoudhury, Arindam
    He, Xinzi
    Prince, Martin R.
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (05)
  • [49] The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
    Tarabzuni, Ola
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [50] IDENTIFYING THE MAIN PREDICTORS OF URINE OUTPUT IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS TAKING TOLVAPTAN
    Borrego-Utiel, Francisco-Jose
    Morales Garcia, Ana Isabel
    Polo Moyano, Aurora
    Roca Oporto, Francisco
    Merino Garcia, Enoc
    Esteban de la Rosa, Rafael Jose
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I4 - I4
12345